
Opinion|Videos|April 15, 2025
Case 1: Experts on a GPP Emergency Case and Effisayil 1 Trial Results
Panelists discuss how a generalized pustular psoriasis (GPP) emergency case highlights the rapid onset, systemic complications, and treatment challenges of this condition, while reviewing Effisayil 1 trial results that demonstrated spesolimab’s efficacy in quickly resolving pustulation through IL-36 pathway inhibition, representing a significant advancement in targeted therapy for acute flares.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
How Galderma is Modernizing Aesthetic Trends and Patient Outcomes Around the World
3
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
4
Dermatology Times January 2026 Print Recap
5








